EGFR and colorectal carcinoma: Therefore, it is evident that it is vitally important to identify a more reliable predictive biomarker of response to anti-EGFR therapy and/or more robust therapeutic targets for monoclonal antibody or small molecule tyrosine kinase inhibitor-based therapy in CRC [3,4].